Our team recently contributed to advances in care in two important areas of neurology.
Alzheimer’s Disease
Early and accurate diagnosis of Alzheimer’s disease is crucial as treatment options become available. Biomarker testing, imaging, and neuropsychiatric assessments are needed to evaluate cognitive impairment.
Fujirebio engaged us to help educate pathologists and neurologists on the importance of AD diagnosis and the current and emerging diagnostic options. This initiative involved the development of an unbranded comprehensive slide library that was used as a foundation to educate internal and external audiences including a webinar targeting neurologists and pathologists and an article in CAP Today.
Migraine
Anti-calcitonin gene-related peptide (CGRP) represents a new and effective treatment option for people suffering with migraine headaches. In collaboration with opinion leaders and the medical affairs team at Alder BioPharmaceuticals, Medical Minds developed an educational initiative to educate headache specialists and other neurologists about the advantages of eptinezumab, an anti-CGRP, delivered via IV infusion. View case study.